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Abstract. 
 
Limb-girdle muscular dystrophy type 2D 
(LGMD 2D) is an autosomal recessive disorder caused 
 
by mutations in the 
 
a
 
-sarcoglycan gene. To determine 
how 
 
a
 
-sarcoglycan deficiency leads to muscle fiber de-
generation, we generated and analyzed 
 
a
 
-sarcoglycan–
deficient mice. 
 
Sgca-
 
null mice developed progressive 
muscular dystrophy and, in contrast to other animal 
models for muscular dystrophy, showed ongoing mus-
cle necrosis with age, a hallmark of the human disease. 
 
Sgca-
 
null mice also revealed loss of sarcolemmal integ-
rity, elevated serum levels of muscle enzymes, in-
creased muscle masses, and changes in the generation 
of absolute force. Molecular analysis of 
 
Sgca-
 
null mice 
demonstrated that the absence of 
 
a
 
-sarcoglycan re-
sulted in the complete loss of the sarcoglycan complex, 
sarcospan, and a disruption of 
 
a
 
-dystroglycan associa-
tion with membranes. In contrast, no change in the ex-
pression of 
 
e
 
-sarcoglycan (
 
a
 
-sarcoglycan homologue) 
was observed. Recombinant 
 
a
 
-sarcoglycan adenovirus 
injection into 
 
Sgca
 
-deficient muscles restored the 
sarcoglycan complex and sarcospan to the membrane. 
We propose that the sarcoglycan–sarcospan complex is 
requisite for stable association of 
 
a
 
-dystroglycan with 
the sarcolemma. The 
 
Sgca
 
-deficient mice will be a valu-
able model for elucidating the pathogenesis of sarcogly-
can deficient limb-girdle muscular dystrophies and for 
the development of therapeutic strategies for this dis-
ease.
Key words: gene targeting • muscular dystrophy • 
sarcoglycan • dystroglycan • sarcospan
 
I
 
N
 
 
 
skeletal and cardiac muscle, dystrophin is associated
with a large complex of sarcolemmal and cytoskeletal
proteins (for reviews see Henry and Campbell, 1996;
Straub and Campbell, 1997; Ozawa et al., 1998). The dys-
trophin–glycoprotein complex (DGC)
 
1
 
 includes 
 
a
 
- and
 
b
 
-dystroglycan, the syntrophins, and the sarcoglycans. The
sarcoglycans are a group of single pass transmembrane
glycoproteins, which form a complex within the DGC,
consisting of 
 
a
 
-, 
 
b
 
-, 
 
g
 
-, and 
 
d
 
-sarcoglycan. Recently the 25-
kD component of the DGC was characterized and named
sarcospan (Crosbie et al., 1997). The DGC confers a struc-
tural link between laminin 2 in the extracellular matrix and
the F-actin cytoskeleton (Ervasti and Campbell, 1993),
and is thought to protect muscle cells from contraction-
induced damage (Weller et al., 1990; Petrof et al., 1993).
Primary mutations in the genes encoding several com-
ponents of the DGC have been associated with muscular
dystrophy (Straub and Campbell, 1997; Ozawa et al.,
1998). In autosomal recessive limb-girdle muscular dystro-
phy (LGMD), mutations in any of the sarcoglycan genes
(Roberds et al., 1994; Bönnemann et al., 1995; Lim et al.,
1995; Noguchi et al., 1995; Nigro et al., 1996) lead to the
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concomitant loss or reduction of all four sarcoglycans (
 
a
 
,
 
b
 
, 
 
g
 
, and 
 
d
 
) from the sarcolemma. Thus far, the BIO 14.6
hamster has served as an animal model for sarcoglycan-
deficient muscular dystrophy (Roberds et al., 1993
 
b
 
). The
hamster has a genomic deletion in the 
 
d
 
-sarcoglycan gene
(Nigro et al., 1997; Sakamoto et al., 1997) that results in re-
duced sarcoglycan levels in striated muscles (Nigro et al.,
1997; Sakamoto et al., 1997). However, mutations in the
human 
 
d
 
-sarcoglycan gene (LGMD 2F) seem to be very
rare compared with the prevalence of 
 
a
 
-sarcoglycan gene
mutations (LGMD 2D) (Duggan et al., 1997). Further-
more, the BIO14.6 hamster reveals a comparatively mild
skeletal muscle pathology and develops a hypertrophic
cardiomyopathy (Homburger, 1979) generally not seen in
patients with primary sarcoglycan deficiency. Generation
of a phenotypically more accurate model of LGMD is
therefore critical for developing effective therapeutic
strategies as well as for elucidating the pathogenesis of the
disease.
In the present study, we have developed 
 
Sgca
 
-null mice
in order to analyze the biological role of the sarcoglycans
in the pathophysiology of LGMD. The null mutant repre-
sents the first engineered animal model for autosomal re-
cessive muscular dystrophy with a primary sarcoglycan
gene defect. The mice developed histopathological fea-
tures of muscular dystrophy shortly after birth and showed
ongoing fiber degeneration until nine months of age. Bio-
chemical analysis revealed loss of the entire sarcoglycan
complex along with a complete loss of sarcospan. Our data
indicate that sarcospan is an integral component of the
sarcoglycan complex. In addition to sarcoglycan/sarcospan
deficiency we observed a reduction of all other DGC com-
ponents. The disruption of the DGC in 
 
Sgca
 
-null mutant
mice resulted in increased masses of both extensor digi-
torum longus (EDL) and soleus muscles and a decrease in
specific force developed by the EDL. We found no alter-
ation in the expression level of 
 
e
 
-sarcoglycan, the recently
identified homologue of 
 
a
 
-sarcoglycan (Ettinger et al.,
1997; McNally et al., 1998). Intramuscular injection of a re-
combinant 
 
a
 
-sarcoglycan adenovirus in homozygous mu-
tants restored expression of the DGC at the sarcolemma,
demonstrating the feasibility of gene transfer for sarco-
glycan-deficient LGMD. Our results suggest that the ab-
sence of the sarcoglycan–sarcospan complex due to a null
mutation in the 
 
Sgca
 
 gene causes dissociation of the DGC
and contributes to progressive muscle degeneration in
LGMD 2D.
 
Materials and Methods
 
Isolation of 
 
a
 
-Sarcoglycan and Vector Construction
 
The 
 
a
 
-sarcoglycan gene was isolated from a 
 
l
 
 FIXII 129/sv genomic li-
brary by homology screening using a radiolabeled human 
 
a
 
-sarcoglycan
cDNA. A 16.2-kb NotI fragment was characterized by restriction map-
ping and limited sequencing (GenBank/EMBL/DDBJ accession number
AF064081). Two StyI fragments of 0.16 and 0.9 kb carrying exon 1 and a
portion of 5
 
9
 
and 3
 
9
 
 contiguous intron were coligated into the XbaI site of
pPNT. Orientation of the two inserted fragments was checked by PCR
and sequencing. A 9-kb fragment containing a portion of intron 3, and
exon 4–exon 9 was amplified using a high-fidelity PCR reaction (Takara,
Shiga, Japan) with intron 3 forward primer from: CCCCTCGAGCCGT-
TCCTCAGACTTTTTATTC and exon 9 reverse primer from: AAT-
GCGGCCGCTCTCCTGTACGAACAT. The PCR fragment was restric-
 
tion digested by NotI and XhoI and inserted into a XhoI-NotI cut
plasmid. Correct targeting replaced exon 2 (containing part of the signal
sequence), exon 3,571 bp of intron 1, and 65 bp of intron 3 with a neomy-
cin resistance gene in opposite transcriptional orientation (see Fig. 1).
 
Generation of Sgca-deficient Mice
 
The NotI linearized construct was introduced into 2 
 
3 
 
10
 
7
 
 R
 
1 
 
ES cells by
electroporation (240 V, 500 
 
m
 
F; Bio-Rad Gene Pulser; Hercules, CA).
The ES cells were maintained on feeder layers and passaged clonally. Tar-
geting fidelity was determined by Southern analysis. Cells from three cor-
rectly targeted clones were microinjected into C57BL/6J blastocysts and
transferred into pseudopregnant recipients. After germ-line transmission,
genotypes were determined by PCR on DNA from tail biopsies (see Fig.
1). The following primers and PCR conditions were used: (
 
a
 
) INT1 in in-
tron 1: CAGGGCTGGGAGCTGGGTTCTG; (
 
b
 
) EX2 in intron 3 (de-
leted in the null allele): CCCAGGGCCTTGATGCCT; and (
 
c
 
) NEOTR:
GCTATCAGGACATAGCGTTGGCTA: first denaturation at 94
 
8
 
C for
5 min, followed by 30 cycles of 1 min at 94
 
8
 
C, 1 min at 64
 
8
 
C, 2 min 30 s at
72
 
8
 
C, and 7 min last extension at 72
 
8
 
C. All three primers were used in the
same PCR reaction. Wild-type and null alleles corresponded to PCR frag-
ments of 1,061 and 618 bp, respectively.
 
Northern Blot Analysis
 
Total RNA from control, heterozygous, and homozygous-null mutant
skeletal and cardiac tissues was extracted using RNAzol (Tel-Test,
Friendswood, TX) according to manufacturer specifications. 30 
 
m
 
g of total
RNA was run on a 1.25% agarose gel containing 5% formaldehyde and
transferred to Hybond N membrane (Amersham Corp., Arlington
Heights, IL). RNA was cross-linked to the membrane using a Stratagene
UV cross-linker (La Jolla, CA). Membranes were then prehybridized and
hybridized using standard methods. Washes were carried out at 65
 
8
 
C in
1
 
3 
 
SSC/1% SDS initially, then 0.1
 
3 
 
SSC/0.1% SDS. Blots were ex-
posed for autoradiography.
 
Evans Blue Dye Injection and Microscopic Evaluation
 
Evans blue dye (EBD) (Sigma Chemical Co., St. Louis, MO) was dis-
solved in PBS (10 mg/ml) and sterilized by passage through membrane fil-
ters with a pore size of 0.2
 
 
 
m
 
m. Mice were injected intravenously with 0.25
 
m
 
l per 10 g of body weight of the dye solution through the tail vein. Ani-
mals were killed 6 h after injection by cervical dislocation. During the time
period between injection and cervical dislocation, animals were kept in
standard laboratory cages. All mice were skinned and inspected for dye
uptake in the skeletal muscles, indicated by blue coloration. Muscle sec-
tions for microscopic Evans blue detection were incubated in ice-cold ace-
tone at 
 
2
 
20
 
8
 
 C for 10 min, and after a rinse with PBS, sections were
mounted with Vectashield mounting medium (Vector Laboratories, Inc.,
Burlingame, CA). Sections were observed under a Zeiss Axioplan fluores-
cence microscope (Carl Zeiss, Inc., Thornwood, NY) or a MRC-600 laser
scanning confocal microscope (Bio-Rad Laboratories, Hercules, CA).
 
Serum Levels of Muscle Enzymes
 
Activities of muscle specific pyruvate kinase (PK) isozyme found in the
blood serum were measured as previously documented (Edwards and
Watts, 1981). Quantitative, kinetic determination of creatine kinase activ-
ity in serum of control and 
 
Sgca
 
-deficient mice was measured using cre-
atine kinase (CK) reagent (Sigma Chemical Co.) according to the manu-
facturer’s instructions. Blood was collected from the retroorbital sinus of
2–18-wk-old mice and the serum was stored at 
 
2
 
80
 
8
 
C before measure-
ments.
 
Antibodies
 
Monoclonal antibodies IIH6 against 
 
a
 
-dystroglycan (Ervasti and Camp-
bell, 1991) and 8D5 against 
 
b
 
-dystroglycan (Lim et al., 1995) were previ-
ously characterized. mAbs 20A6 against 
 
a
 
-sarcoglycan, 5B1 against
 
b
 
-sarcoglycan, and 21B5 against 
 
g
 
-sarcoglycan were generated in collabo-
ration with L.V.B. Anderson (Newcastle General Hospital, Newcastle
upon Tyne, UK). We used a mAb against caveolin-3 (Transduction Labo-
ratories, Lexington, KY). Rabbit polyclonal antibodies against 
 
a
 
-sarco-
glycan (Roberds et al., 1993
 
a
 
), dystrophin, and utrophin (Ohlendieck et
al., 1991
 
a
 
), neuronal nitric oxide synthase (Crosbie et al., 1998), the 
 
a
 
1
 
subunit of the dihyrdopyridine receptor (Ohlendieck et al., 1991
 
b
 
), and 
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a
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the laminin 
 
a
 
2-chain (Allamand et al., 1997) were described previously.
Two affinity-purified rabbit antibodies (rabbit 208 and 215) were pro-
duced against a full-length COOH-terminal fusion protein of 
 
g
 
-sarcogly-
can, and against an NH
 
2
 
-terminal peptide (MMPQEQYTHHRSTMP-
GAA) of 
 
d
 
-sarcoglycan, respectively. An affinity-purified goat antibody
(goat 26) was produced against a NH
 
2
 
-terminal fusion protein of 
 
b
 
-sar-
coglycan containing amino acids 1–65. Polyclonal antibodies against
 
a
 
-dystroglycan fusion protein D were affinity-purified from goat 20
(Ibraghimov-Beskrovnaya et al., 1992). An affinity-purified rabbit anti-
body (rabbit 235) was produced against a COOH-terminal fusion protein
of sarcospan (CFVMWKHRYQVFYVGVGLRSLMASDGQLPKA). Two
polyclonal antibodies against 
 
e
 
-sarcoglycan were used. One was previ-
ously characterized (Ettinger et al., 1997) and the other (rabbit 232) was
generated against a COOH-terminal peptide of 
 
e
 
-sarcoglycan (PHQT-
QIPQQQTTGKWYP).
 
Immunofluorescence Analysis
 
For immunofluorescence analysis, 7-
 
m
 
m transverse cryosections were pre-
pared from control and 
 
Sgca
 
-null mutant skeletal and cardiac muscle. All
procedures were performed at room temperature. Sections were blocked
with 5% BSA in PBS for 1 h and then incubated with the primary antibod-
ies for 90 min. After washing with 1% BSA/PBS, sections were incubated
with Cy3-conjugated secondary antibodies (1:250) for 1 h and then
washed with 1% BSA/PBS. After a rinse with PBS, sections were
mounted with Vectashield mounting medium (Vector Laboratories, Inc.)
and observed under a Zeiss Axioplan fluorescence microscope (Carl Zeiss
Inc.).
 
Immunoblot Analysis of Membrane Preparations
 
KCl-washed membranes from skeletal and cardiac muscle were prepared
as described previously (Ohlendieck et al., 1991
 
b
 
) with the addition of two
protease inhibitors, calpeptin and calpain inhibitor I (Calbiochem-Nova-
biochem Corp., San Diego, CA). Both inhibitors were used in the buffers
at a concentration of 2 nM. Membranes were resolved by SDS-PAGE
(Laemmli, 1970) on 3–15% linear gradient gels and transferred to nitro-
cellulose membranes (Towbin et al., 1979). Immunoblot staining was per-
formed as previously described (Ohlendieck et al., 1991
 
b
 
).
 
Contractile Properties
 
For the measurement of contractile properties of the EDL or soleus mus-
cles of control or 
 
Sgca
 
-deficient mice in vitro, mice were anesthetized with
sodium pentobarbital (30–50 mg/kg for control or 
 
Sgca
 
-deficient mice, re-
spectively) (Nembutal; Abbott Laboratories, Chicago, IL). Contractile
properties were measured on 28 muscles, seven EDL and five soleus mus-
cles from heterozygous littermates of 
 
Sgca
 
-deficient mice and 10 EDL and
six soleus muscles from eight 
 
Sgca
 
-null mutant mice. Muscles were iso-
lated and removed carefully from the anesthetized mice and immersed in
an oxygenated (95% O
 
2
 
 and 5% CO
 
2
 
) bath containing a buffered mam-
malian Ringer’s solution, pH 7.4, which included curare. The solution was
maintained at 25
 
8
 
C. The tendons were tied securely to a servomotor and a
force transducer. Muscles were stimulated directly by the current flow be-
tween two large platinum electrodes (Brooks and Faulkner, 1988). The
voltage of the stimulator was set to provide maximum twitch force and
the muscle length was set at optimum length for force development. With
the muscle at optimum length, the frequency of stimulation was increased
until force plateaued at maximum isometric tetanic force (
 
P
 
o
 
). After the
measurement of Po, the length of the muscle was set at 90% of the fiber
length and with the muscle passive the muscle was stretched to 110% of fi-
ber length at 1 fiber length(s) and then returned at the same velocity to
90% of fiber length. The peak force at the end of the stretch was used as a
measure of the resistance to stretch of the passive muscle. The muscle was
removed from the bath, blotted, and weighed to obtain the muscle mass.
Based on the direct measurements of muscle mass, muscle length, fiber
length, and Po, total fiber cross-sectional area and specific Po were calcu-
lated. The total fiber cross-sectional area (mm2) was calculated by divid-
ing the muscle mass (mg) by the fiber length (mm) and then by 1.06 (g/
cm2) to correct for the muscle density (Brooks and Faulkner, 1988). The
force (kN) was divided by the total fiber cross-sectional area (m2) to ob-
tain an estimate of the specific force (kN/m2) of the EDL and soleus mus-
cles. Each data set was analyzed by a two-way analysis of variance
(ANOVA) in a general linear model algorithm appropriate for unequal
sample sizes (Statistical Analysis System, Gary, NC). In circumstances
where the overall F-ratio for the ANOVA was significant, the differences
between individual group means were determined by post hoc pairwise
t-comparisons of least square means with appropriate correction of the
significance level to account for multiple comparisons. Significant differ-
ences between data on control and Sgca-deficient mice are indicated in
Fig. 6 by asterisks. Significance was set a priori at P , 0.05.
Recombinant Adenovirus Injections
The human a-sarcoglycan cDNA sequence was subcloned into the
pAdRSVpA adenovirus vector through standard methods of homologous
recombination with Ad5 backbone dl309 by the University of Iowa Gene
Transfer Vector Core. Lysates from the infected cells were collected and
tested for the expression of a-sarcoglycan using a polyclonal antibody.
Recombinant viruses were plaque purified three times, amplified, and
then concentrated using established methods (Graham and Eb, 1973;
Davidson et al., 1994). Recombinant adenovirus injections were per-
formed as previously described (Holt et al., 1998). For 2-d-old Sgca-null
mutant mice, the adenovirus was injected directly through the skin into
the hamstring. 3-wk-old mice were anesthetized by intraperitoneal injec-
tion of sodium pentobarbital at a calculated dose of 50 mg/kg. A human
d-sarcoglycan adenovirus (Holt et al., 1998) was used as control.
Results
Generation of Sgca-null Mutant Mice
To design a targeting vector to generate Sgca-null mice,
we cloned the murine homologue of the human SGCA
gene from a mouse genomic library. Murine and human
a-sarcoglycan are highly related at the amino acid level
and their expression pattern at the mRNA level is similar
(Roberds et al., 1994; Liu et al., 1997). The structural orga-
nization of the gene into 10 exons is shared by both species
(GenBank/EMBL/DDBJ accession number AF064081).
Targeted inactivation of one of the Sgca alleles was ac-
complished by replacement of exons 2 and 3 and flanking
intronic sequences with the neomycin resistance gene (Fig.
1 a). The targeting construct was designed to create a mu-
tant allele of Sgca representative of certain human muta-
tions. One-third of a-sarcoglycan mutations characterized
to date affect exons 2 and 3 of the SGCA gene (Piccolo et
al., 1995; Carrie et al., 1997). A total of 1,023 colonies sur-
viving G418 and gancyclovir selection were analyzed by
Southern-blotting for the presence of homologous recom-
bination (Fig. 1 b). Two clones yielded chimeras producing
germ-line transmission. Transmission of the mutant allele
followed normal Mendelian segregation ratios for an auto-
somal recessive gene in mice derived from both clones.
Homozygous mutant and heterozygous newborn pups ap-
peared healthy, showing no gross developmental abnor-
malities compared with control littermates.
To determine if the targeting approach produced a null
allele, we evaluated tissues from homozygous mutants and
heterozygous mice, and compared them to wild-type mice.
Northern blot analysis using a probe against the full-length
coding sequence revealed the absence of a-sarcoglycan
transcript in Sgca-deficient skeletal and heart tissue from
the two independently derived lines (Fig. 1 d and data not
shown). In contrast to control and heterozygous animals,
no a-sarcoglycan expression was detected in the homozy-
gous mutant mice (Fig. 1 e). Reverse transcription (RT)-
PCR revealed the presence of a minor transcript in skele-
tal muscle RNA resulting from the use of cryptic splice
sites in the neomycin cassette in homozygous mutants and
heterozygous mice. Sequencing of the RT-PCR productThe Journal of Cell Biology, Volume 142, 1998 1464
revealed that this mutant transcript encoded exon 1 and a
stretch of 516 bp from the inverted neo cassette spliced
with exon 4 of the Sgca gene (data not shown). Unexpect-
edly, this aberrant splicing event inserted 172 amino acids
from the noncoding strand of the neo cassette, maintaining
the frame with exon 4. Translation of the altered transcript
would produce a protein lacking the 91 amino acids en-
coded by exons 2 and 3, including part of the signal se-
quence. Using a COOH-terminal peptide antibody and
mAb 20A6 against a-sarcoglycan, this mutant protein
could not be detected in Sgca-deficient skeletal and car-
diac tissues by immunoblot or immunofluorescence analy-
sis (Fig. 1 e and see Figs. 4 and 5).
Sgca-null Mutant Mice Display a Progressive
Muscular Dystrophy
Sgca-null mutant mice did not show any overt signs of a
myopathy, and were in this respect similar to dystrophin
deficient mdx mice. To examine the progression of the
muscular dystrophy in these mutant mice, haematoxilin
and eosin (H & E)-stained frozen sections of the sural tri-
ceps and the diaphragm muscles were evaluated between
the ages of 8 d and 9 mo. Pathology characteristic of mus-
cular dystrophy was observed in every Sgca-deficient
mouse but never in control animals. The earliest changes
consisted of widely scattered clusters of necrotic myocytes
or regenerating myocytes with internally placed nuclei
(Fig. 2). These clusters increased in both number and size
as the mice increased in age (Fig. 2). Based on the evalua-
tion of 200–1,100 myocytes per muscle, the number of
nonregenerating myocytes with internally placed nuclei
also increased with age. At 8 d, between 1 and 2.5% of the
sural triceps and diaphragm myocytes already showed cen-
tral nuclei, respectively. These numbers continuously in-
creased and at 8–16 wk of age more than 70% and as high
as 99% of the Sgca-deficient myocytes contained central
nuclei (Fig. 2). In wild-type mice on the other hand, the
numbers of centrally placed nuclei never exceeded 1%.
In addition to necrosis, regeneration, and central nucle-
ation, a broad spectrum of other dystrophic changes was
also noted in Sgca-deficient muscle (Fig. 2). The most
prominent of these included atrophy, hypertrophy, fiber
splitting, and endomysial fibrosis. In some Sgca-deficient
mice 8 wk of age or older, dystrophic calcification was
noted in association with myocyte necrosis (Fig. 2). Fatty
infiltration was present in some of the muscles from 16-
wk-old mice. A qualitative comparison of fiber type distri-
bution assessed with ATPase staining as well as staining
characteristics with NADH and Gomori trichrome stains
suggested no substantial additional differences between
null mutant and wild type mice at any age (data not
shown). The homozygotes from both correctly targeted
cell lines demonstrated an identical dystrophic phenotype.
Sarcolemmal Integrity in
a-Sarcoglycan–deficient Muscle
To test whether the mutation of the a-sarcoglycan gene
leads to damage of the plasma membrane, we intrave-
nously injected Sgca-deficient mice with Evans blue dye
(EBD), a normally membrane impermeant molecule. This
dye penetrates into the cytoplasm of fibers with compro-
mised sarcolemmal integrity (Matsuda et al., 1995; Straub
Figure 1.  Generation of Sgca-null mutant
mice. (a) Restriction map of the wild-type
Sgca locus (Sgca1), the targeting con-
struct, and the targeted locus. A region of
902 bp including exons 2 and 3 (E2 and
E3) was deleted and replaced by a phos-
phoglycerate kinase-neomycin cassette
(NEOR). (b) Southern blot analysis. Using
the probe shown (black box), the targeted
locus contains an EcoR1 fragment of 8.8
kb, whereas the intact allele shows a 5.5-
kb band: clone 594 is correctly targeted.
(c) Genotyping by PCR. Primer sites are
shown in a; using primers INT1 and EX2
the wild-type allele (1/1) corresponds to
a 1,061-bp fragment; using primers INT1
and NEOTR, the null allele is 618 bp. (d)
Northern blotting. An a-sarcoglycan cDNA
probe reveals the correct sized transcript
in wild type (1/1) and heterozygotes
(1/2) from 30 mg total RNA extracted
from skeletal muscle; homozygous mu-
tant tissue shows no a-sarcoglycan tran-
script. (e) Western blot analysis. Using an
affinity-purified polyclonal antibody against
a COOH-terminal peptide of a-sarcogly-
can, membrane-enriched preparations of
skeletal muscle reveal the protein in (1/1),
and (1/2), but not in (2/2).Duclos et al. a-Sarcoglycan–deficient Muscular Dystrophy 1465
et al., 1997). No obvious uptake of the blue tracer into
skeletal muscles of heterozygous and control mice was de-
tected by macroscopic inspection. In contrast, EBD up-
take was consistently observed in skeletal muscle fibers of
4–20-wk-old homozygous-null mutants. The extent of
EBD accumulation varied among muscles. Areas of blue
staining appeared mainly within the proximal limb mus-
cles and the muscles of the pelvic and the shoulder girdle.
Skeletal muscles which macroscopically showed dye up-
take always revealed red EBD autofluorescence by fluo-
rescence microscopy analysis (Fig. 3 a). Most EBD-posi-
tive fibers showed intense staining, whereas the signal was
faint in others. Interestingly, EBD-positive fibers were dis-
tributed in clusters throughout the different muscles (Fig.
3 a). Fibers that had taken up the tracer and were assumed
to have pathologic plasma membrane permeability often
showed characteristic features of degeneration and necro-
sis by H & E staining. In contrast, dye uptake was not
readily visible in cardiac muscle by macroscopic inspec-
tion, and microscopic analysis revealed no EBD in cardi-
omyocytes of control or diseased animals.
We also evaluated membrane damage in Sgca-deficient
mice by determining the release of muscle enzymes into
the circulating blood. Therefore we measured muscle-spe-
cific serum PK (Fig. 3 b) activity and serum CK activity. In
7–10-wk-old wild-type and heterozygous mice we found
normal serum levels of PK activity. Age-matched homozy-
gous mice, on the other hand, exhibited high serum levels
of PK activity similar to that of mdx mice, indicating that
membrane damage occurred to comparable extents in
Sgca-null mutants as in mdx mice (Fig. 3 b). Similarly, in
older animals (up to 18 wk of age) we found no differences
in PK activity between Sgca-null mice and age-matched
mdx mice. The serum CK activity was z10 times higher in
Sgca-deficient mice compared with control animals (data
not shown).
Loss of Sarcoglycan and Sarcospan Expression in
Sgca-null Mutant Mice
Immunofluorescence analysis was performed for each
component of the sarcoglycan complex. In Sgca-deficient
mice, a-sarcoglycan protein was absent from the sarco-
lemma of skeletal and cardiac muscle fibers. In addition,
there was a concomitant drastic reduction of b-, g-, and
d-sarcoglycan (Fig. 4, a and b). Other components of the
DGC were also examined by immunofluorescence micros-
copy. The laminin-a2 chain and b-dystroglycan were
present at comparable levels with control muscle (Fig. 4, a
and b). We observed a slight reduction in the a-dystrogly-
can staining in Sgca-deficient muscle compared with con-
trol muscle. However, the sarcolemmal staining for dystro-
phin was consistently patchy and reduced in Sgca-null
mutant skeletal muscle, although dystrophin staining in
Figure 2.  Histological analysis of Sgca-
deficient diaphragm muscle. Sgca-null mu-
tant mice started to develop a progressive
muscular dystrophy at 1 wk of age and, in
contrast to mdx mice, showed ongoing
muscle necrosis with increasing age. Ex-
amples of muscle pathology in the dia-
phragm of different aged mice are demon-
strated. (a) Myocyte atrophy (small fibers
scattered throughout the micrograph) and
central nucleation (see fibers near the cen-
ter and in upper left quadrant) after regen-
eration in an 8-d-old mouse. (b) A small
focus of myocyte necrosis (center) with
surrounding regenerating and atrophic fi-
bers in an 18-d-old mouse. (c) Skeletal
muscle of a 4-wk-old mouse with ongoing
necrosis (right of center), regeneration,
central nucleation, endomysial fibrosis
(increase in tissue between muscle fibers),
atrophy, hypertrophy (large fibers in left
lower quadrant), and fiber splitting. (d)
The edge of a large, confluent area of
acute myocyte necrosis in an 8-wk-old
mouse. (e) More severe endomysial fibro-
sis with atrophy, central nucleation, fiber
splitting, and dystrophic calcification
(dark structures in lower right) in an 8-wk-
old mouse. (f) Small foci of myocyte ne-
crosis surrounded by atrophic and hyper-
trophic fibers, central nucleation, and fiber
splitting are shown in a 16-wk-old mouse.
All panels show 7-mm frozen sections of
diaphragm muscle stained with H & E.The Journal of Cell Biology, Volume 142, 1998 1466
heart appeared similar to control (Fig. 4, a and b). We also
analyzed expression of the newly identified e-sarcoglycan
(Ettinger et al., 1997) and the 25-kD DGC component
sarcospan (Crosbie et al., 1997). In contrast to the
other sarcoglycans, skeletal and cardiac muscle staining
for e-sarcoglycan in Sgca-deficient mice was comparable
to control levels. Interestingly, sarcospan was absent along
with the sarcoglycans at the sarcolemma of homozygous-
null mice (Fig. 4, a and b), indicating that sarcospan may
be an integral component of the sarcoglycan complex.
Dissociation of the DGC in Sgca-null Mutant Mice
To further examine the expression of DGC components,
immunoblot analysis was performed on isolated mem-
brane preparations from control and homozygous mutant
skeletal muscle. We observed that Sgca-deficient muscle
preparations were more susceptible to proteolytic degra-
dation. Use of calpain inhibitor I and calpeptin reduced
degradation in the membrane preparations from Sgca-null
mice. The ryanodine receptor and dystrophin, for exam-
ple, were almost completely degraded in skeletal muscle
membrane preparation without the use of calpain inhibi-
tor I and calpeptin. Coomassie blue staining (data not
shown) and staining for caveolin-3, the a1 subunit of the
dihydropyridine receptor, and the ryanodine receptor
(data not shown) showed that equivalent levels of mem-
brane protein were present in control and homozygous
mutant preparations (Fig. 5). a-Sarcoglycan was not de-
tected in skeletal and cardiac membrane preparations
from  Sgca-null mice (refer to Fig. 1 e, Fig. 5, and data not
shown). Heterozygotes expressed control levels of a-sar-
coglycan (Fig. 1 e). b-, g-, and d-sarcoglycan were greatly
reduced in a-sarcoglycan–deficient skeletal muscle mem-
branes compared with control muscle (Fig. 5). Dystrophin
was slightly reduced in accordance with the patchy stain-
ing observed by immunofluorescence. Together with the
dystrophin reduction we also found reduced levels of the
free radical-producing enzyme neuronal nitric oxide syn-
thase, which is anchored to the sarcolemma by dystrophin
(Brenman et al., 1995). Utrophin, the autosomal homo-
logue of dystrophin, was found at higher levels in mem-
brane-enriched preparations from homozygous mutant
mice compared with control mice. This observation could
be related to the large number of regenerating fibers in
Sgca-deficient muscle, which would be expected to express
higher levels of utrophin (Helliwell et al., 1992). In addi-
tion, a- and b-dystroglycan were reduced in membrane
preparations of dystrophic mice compared with control
mice (Fig. 5), whereas immunofluorescence showed only
little dystroglycan reduction at the sarcolemma (Fig. 4). In
the supernatant from Sgca-deficient membrane prepara-
tions, a-dystroglycan was enriched and fully glycosylated
but was not tightly associated with membranes (data not
shown). Thus, a-dystroglycan is synthesized correctly but
is not stably anchored to the sarcolemma in the absence of
the sarcoglycan complex. In addition, Western blot analysis
confirmed the immunofluorescence analysis in showing that
dystrophin was no longer tightly held at the skeletal plasma
membrane in the absence of the sarcoglycan complex.
Abnormal Contractile Properties of
Sgca-deficient Muscles
The body masses of 8-wk-old Sgca-null mutant mice (34 6
1 g) were not significantly different from their heterozy-
gous littermates (31 6 1 g) (Fig. 6). For the EDL muscles
of the Sgca-deficient mice compared with heterozygous
littermates, the masses were 40% greater, whereas the ab-
solute forces were not significantly different. As a con-
sequence, the specific Po of the EDL muscles of Sgca-defi-
cient mice was 31% lower than that of the control mice.
The resistance to stretch of the passive muscle in homozy-
gous null mutants was 75% greater than the values for
control animals. In contrast to the changes observed in the
EDL muscles, the soleus muscles in the Sgca-null mutant
mice responded in a completely different manner. Com-
pared with soleus muscles in heterozygous littermates,
those in the Sgca-null mutant mice had a 62% greater
mass, a 39% greater absolute Po, and no significant differ-
ence in either specific Po or resistance to stretch.
Figure 3.  Evaluation of sarcolemma permeability. (a) Heterozy-
gous (1/2) and homozygous-null (2/2) mice were intravenously
injected with EBD. The panels show dye uptake into muscle fi-
bers of the femoral quadriceps and diaphragm muscles 6 h after
injection. Dye accumulation was only detected in skeletal muscle
from Sgca-null mutants. Activity of muscle-specific PK in 7–10-
wk-old wild-type (1/1), heterozygotes (1/2), homozygotes (2/2),
and mdx mice (b). Measurement of PK released from the muscle
fiber into the circulating blood showed similar high levels of PK
activity in (2/2) and mdx mice compared with (1/2) and control
(1/1). Error bars indicate the standard deviation where n equals
the number of mice in each set. Bar, 50 mm.Duclos et al. a-Sarcoglycan–deficient Muscular Dystrophy 1467
Restoration of the Sarcoglycan–Sarcospan Complex
by Gene Transfer
We used an adenovirus construct encoding human a-sar-
coglycan to test the ability of exogenously provided a-sar-
coglycan cDNA to restore the sarcoglycan–sarcospan
complex in Sgca-deficient skeletal muscle. To circumvent
a possible immune response against the neoantigen or ad-
enovirus itself, the a-sarcoglycan adenovirus was injected
into the hamstring muscles of 2-d-old Sgca-deficient pups.
We found high levels of a-sarcoglycan expression at the
sarcolemma (Fig. 7) over a time interval between 5 d and 2
mo after injection. In addition, a-sarcoglycan–positive fi-
Figure 4. Immunofluores-
cence analysis of sarcolemma
proteins in Sgca-deficient
skeletal and cardiac muscle.
Skeletal (a) and cardiac (b)
muscle cryosections from
wild-type (1/1) and Sgca-
null (2/2) mice were stained
with antibodies against dys-
trophin (DYS), a-dystrogly-
can (a-DG), b-dystroglycan
(b-DG), laminin a2-chain,
(lama2),  a-,  b-,  g-,  d-, and
e-sarcoglycan (SG), and sar-
cospan (SPN). The sarco-
glycans and sarcospan were
drastically reduced in the
Sgca-deficient muscle whereas
the a-sarcoglycan homologue
e-sarcoglycan was present in
comparable amount to con-
trol. Dystrophin staining is
reduced in Sgca-null mutant
mice from the sarcolemma of
skeletal muscle, whereas it is
maintained at equal levels to
control in cardiomyocytes.
Bar, 50 mm.The Journal of Cell Biology, Volume 142, 1998 1468
bers revealed expression of the entire sarcoglycan com-
plex, sarcospan and dystrophin by immunofluorescence
microscopy (Fig. 7). Immunostaining of the sarcoglycans
was found in up to 70% of fibers. Interestingly, central nu-
cleation was reduced in Sgca-null mutant muscle after in-
jection of the a-sarcoglycan adenovirus (data not shown).
An adenovirus construct encoding human d-sarcoglycan
was used as a control for the gene transfer studies. In
a-sarcoglycan–deficient muscles injected with the d-sar-
coglycan adenovirus, no reconstitution of the complex was
detected.
Discussion
Progressive muscle weakness initially in pelvic and shoul-
der girdle muscles is a hallmark of patients with a primary
sarcoglycan gene defect. Mutations in the a-sarcoglycan
gene have been well documented and are associated with
the deficiency of the entire sarcoglycan complex from the
sarcolemma (Roberds et al., 1994; Hayashi et al., 1995;
Passos-Bueno et al., 1995; Piccolo et al., 1995; Duggan et
al., 1996). To ascertain how the sarcoglycan defect causes
muscular dystrophy, we evaluated structural and func-
tional characteristics of skeletal and cardiac muscle in
Sgca-null mutant mice.
In contrast to the other sarcoglycans, expression of
a-sarcoglycan is specifically restricted to striated muscle
fibers (Roberds et al., 1993a; Ettinger et al., 1997; Eymard
et al., 1997; Liu et al., 1997). During development, the ex-
pression of a-sarcoglycan is coincident with primary myo-
genesis (Yuan et al., 1990; Liu et al., 1997). In particular,
these studies indicated that at 17 d of gestation in rabbit,
a-sarcoglycan was already present in all myotubes, where
it was confined to the cell periphery (Jorgensen et al.,
1990; Yuan et al., 1990). Similarly, it has been reported
that a-sarcoglycan in mice was not detected before the on-
set of myogenesis, whereas it was expressed at the sarco-
lemma of newly formed fibers at day E14 (Liu et al., 1997).
Targeted disruption of the a-sarcoglycan gene in ho-
mozygous mutants resulted in the absence of normal tran-
script and protein. Analysis of skeletal muscle histology
demonstrated that Sgca-deficient mice presented with a
progressive muscular dystrophy similar to human sarco-
glycan deficient LGMD. The histological changes appeared
as early as 1 wk of age and extended to most skeletal mus-
cles as evidenced by EBD incorporation and elevated
serum PK levels. The presence of extensive central nucle-
ation, connective tissue proliferation, increased variability
of muscle fiber diameter, and necrotic fibers was docu-
mented during the entire course of the disease studied to
date. One striking observation was the persistence of de-
generation and regeneration with extensive areas of ne-
crosis in a-sarcoglycan–deficient muscle. The early onset
and the severity and persistence of the pathology distin-
guished the Sgca-null mutant mice from mdx mice, in
which these features decline after a regeneration peak at
3–4 wk of age (McArdle et al., 1995). Dystrophic pathol-
ogy in the Sgca-null mutant mice is more similar to what
has been documented in mdx/utrn2/2 double-knockout
mice (Deconinck et al., 1997; Grady et al., 1997). The com-
plete absence of sarcospan in addition to the loss of the
sarcoglycan complex may be one reason for the severity of
the disease. The complete lack of sarcospan expression in
Sgca-null mice suggests that sarcospan is an integral com-
Figure 5. Immunoblot analysis of skeletal muscle membranes.
Skeletal muscle microsomes from control (1/1) and Sgca-defi-
cient (2/2) mice were analyzed by 3–15% SDS-PAGE and im-
munoblotting using antibodies against several DGC components.
In particular we used antibodies against the sarcoglycans (a-, b-,
g-, d-, and e-SG), dystroglycans (a- and b-DG), and dystrophin
(DYS). In addition we stained blots with antibodies against neu-
ronal nitric oxide synthase (NOS), which has been shown to be
associated with dystrophin, and the dystrophin homologue utro-
phin (UTR). To demonstrate equal loading of protein samples we
used the a1 subunit of the dihydropyridine receptor (a1-DHPR)
and caveolin-3 (CAV-3) as positive markers.
Figure 6.  Abnormal contractile properties of Sgca-deficient
muscle. The data on EDL and soleus muscles of the Sgca-null
mutant mice are represented as a percentage of the values for
muscles of control mice. The diagram shows bar graphs for the
data on body mass, muscle mass, absolute maximum isometric te-
tanic force, specific force, and peak force during resistance to
stretch of passive muscles. Asterisk, significant differences be-
tween the data obtained in Sgca-deficient and control mice. All
data are presented as the mean 6 one SEM.Duclos et al. a-Sarcoglycan–deficient Muscular Dystrophy 1469
ponent of the sarcoglycan complex. Correct assembly and
proper transportation of the sarcoglycan–sarcospan com-
plex to the plasma membrane seems to be prevented by
the null mutation in the Sgca-gene. Investigation of a-sarco-
glycan–deficient hearts revealed no gross morphological
changes in animals up to 8 mo of age, which is in contrast
to what has been observed for the sarcoglycan-deficient
BIO 14.6 hamster, which starts to develop hypertrophic
cardiomyopathy between 30 and 60 d of age (Homburger,
1979). It will be of interest to observe if cardiac pathology
manifests as mice age.
Immunoblot analysis of membrane-enriched prepara-
tions demonstrated that a-dystroglycan binding to the sar-
colemma was greatly destabilized by loss of the sarcogly-
can–sarcospan complex. Our findings provide new clues
on the molecular interactions between the components of
the DGC. On the one hand, reduction of dystrophin re-
moved a major F-actin binding site from the sarcolemma,
whereas on the other hand, unbound a-dystroglycan elimi-
nated the major sarcolemmal laminin-binding site. Free
a-dystroglycan could be detected in the supernatant of
membrane preparations confirming that it is synthesized,
as observed by immunofluorescence, and glycosylated.
This result suggests that the sarcoglycan–sarcospan com-
plex anchors a-dystroglycan to the sarcolemma. Further-
more, a direct or mediated interaction of the sarcoglycan–
sarcospan complex with dystrophin is implicated by our
findings. The interaction of dystrophin with b-dystrogly-
can does not seem to be sufficient enough to maintain a
solid anchorage of dystrophin to the sarcolemma. The de-
crease of dystrophin is in accordance with reduced levels
of neuronal nitric oxide synthase, which has been reported
to bind to dystrophin (Brenman et al., 1995). Reduced dys-
trophin expression has also been reported in patients with
sarcoglycan-deficient LGMD (Vainzof et al., 1996).
During membrane preparations, we found that isolated
muscle membranes of Sgca-null mice were more degraded
than control membranes. The degradation process could
be prevented by the use of calcium-activated protease in-
hibitors, calpeptin, and calpain inhibitor I. Our results im-
plicate that compared with control muscle, sarcoglycan-
deficient muscle tissue contains an increased amount of
proteases, which may be activated during the membrane
preparation. Several studies provided indirect evidence
consistent with a role for calpains in DMD and mdx pa-
thology (Kumamoto et al., 1995; Spencer et al., 1995).
The structural destabilization of the sarcolemma by loss
of the entire sarcoglycan complex and sarcospan resulted
in dramatically different adaptations in the EDL and so-
leus muscles. Both muscles showed significant hypertro-
phy in response to the a-sarcoglycan deficiency. Hypertro-
phy of skeletal muscles has also been reported in the limb
muscles of mdx mice (Faulkner et al., 1997), but not of the
magnitude observed here. The hypertrophy was function-
ally less effective in the EDL muscles of the Sgca-null mu-
tant mice in which the absolute force was unchanged and
specific force decreased compared with control EDL mus-
cles. In contrast, the greater hypertrophy in the weight-
bearing soleus muscles produced a considerable gain in
absolute force and a value for specific force equivalent to
that of soleus muscles in heterozygous litter mates. The
mechanisms underlying these major adaptive responses to
the a-sarcoglycan deficiency will require further investiga-
tion.
In mdx mice, pathology is thought to be attenuated be-
cause dystrophin is partially replaced by its autosomal ho-
mologue utrophin (Deconinck et al., 1997; Grady et al.,
1997). To test whether lack of a-sarcoglycan was compen-
sated by a protein homologue, we assessed the expression
of e-sarcoglycan in Sgca-null mutant animals. e-sarcogly-
can shares 44% identity with a-sarcoglycan at the amino
acids level (Ettinger et al., 1997), but is only weakly ex-
pressed at the sarcolemma (Ettinger et al., 1997). In the
Sgca-deficient mice, e-sarcoglycan appeared to be nor-
mally expressed at the sarcolemma and in the capillaries of
skeletal and cardiac tissue. Thus, e-SG does not seem to be
an additional member of the known tetrameric complex of
a-, b-, g-, and d-sarcoglycan in skeletal muscle. Neverthe-
less, the presence of e-SG may suggest that it could be part
of a distinct complex at the sarcolemma.
Figure 7. Restoration of sarcoglycan com-
plex after adenovirus injection. Recombi-
nant  a-sarcoglycan adenovirus mediates
restoration of DGC components to the
sarcolemma. 2-d-old Sgca-null mutant
pups were injected in their hamstring mus-
cle with a recombinant a-sarcoglycan ade-
novirus containing the human a-sarco-
glycan coding sequence under the control
of a viral RSV promoter. Serial transverse
cryosections of injected muscle after 3 wk,
were stained with antibodies against a-sar-
coglycan (a), b-sarcoglycan (b), g-sarco-
glycan (c), and d-sarcoglycan (d), dystro-
phin (e), and sarcospan (f). Bar, 50 mm.The Journal of Cell Biology, Volume 142, 1998 1470
Intramuscular injection of recombinant adenovirus was
performed to test the potential of a-sarcoglycan to restore
the sarcoglycan–sarcospan complex in the Sgca-deficient
mice. Our results demonstrated that in fibers which harbored
the a-sarcoglycan recombinant adenovirus, complete as-
sembly and restoration of the sarcoglycan–sarcospan com-
plex to the sarcolemma has occurred. Of particular note,
high efficiency gene transfer was achieved when the a-sarco-
glycan adenovirus was injected at an early stage of life,
preceding the onset of muscle damage and establishment
of immunity. These experiments have broad implications
for the development of gene therapy for LGMDs with a
primary sarcoglycan deficiency. They confirm the feasibil-
ity of these procedures which are facilitated by the small
size of sarcoglycan coding sequences compared with dys-
trophin. They also suggest that a genetic intervention
should be performed as early as possible to circumvent
both the extension of the dystrophic process and the im-
mune response. The Sgca-deficient mice will be a valuable
model for the development of therapeutic strategies for
sarcoglycan deficient LGMD.
Overall, our results suggest that the absence of the
sarcoglycans and sarcospan due to a null mutation in the
Sgca gene causes dissociation of the DGC and contributes
to progressive muscle degeneration in LGMD 2D. We
propose that the sarcoglycan–sarcospan complex is requi-
site for the stable association of a-dystroglycan with the
sarcolemma.
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